Brief: Theratechnologies Reports Q2 Results

Theratechnologies

15/07/2021 12:22

July 15 (Reuters) - Theratechnologies Inc  TH.TO :
    * THERATECHNOLOGIES INC -  DISCUSSIONS WITH FDA AND EMA ON
TRIAL
DESIGN ARE COMPLETE FOR EVALUATING TESAMORELIN IN NASH
    * THERATECHNOLOGIES INC - PHASE 3 CLINICAL TRIAL WILL
INCLUDE
PARTICIPANTS IN U.S. AND EUROPE
    * THERATECHNOLOGIES INC - QTRLY CONSOLIDATED REVENUE WAS
$17.8
MILLION
    * THERATECHNOLOGIES INC - NET LOSS FOR Q2 $0.07 PER SHARE
    * THERATECHNOLOGIES INC - PARTNER IDENTIFICATION AND
NEGOTIATIONS
WILL ALTER INITIATION OF PHASE 3 TRIAL THAT WAS PREVIOUSLY
EXPECTED IN Q3 2021
    * THERATECHNOLOGIES INC - FINAL PHASE 3 CLINICAL TRIAL
DESIGN WILL
RESULT IN HIGHER COSTS THAN WHAT COMPANY HAD PREVIOUSLY
ESTIMATED
    * THERATECHNOLOGIES INC - EVALUATING OPTIONS TO BEST EXECUTE
LATE-STAGE DEVELOPMENT PROGRAM, INCLUDING SEEKING A POTENTIAL
PARTNER

Source text for Eikon:  ID:nGNX4vKvq7 
Further company coverage:  TH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))